A carregar...
Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab
BACKGROUND: Leronlimab, a monoclonal antibody blocker of C-C chemokine receptor type 5 originally developed to treat human immunodeficiency virus infection, was administered as an open-label compassionate-use therapeutic for coronavirus disease 2019 (COVID-19). METHODS: Twenty-three hospitalized sev...
Na minha lista:
| Publicado no: | Clin Infect Dis |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7665416/ https://ncbi.nlm.nih.gov/pubmed/33079180 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciaa1583 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|